CEACAM5 and breast cancer: In 8 breast cancer patients with stage IV disease in which PIK3CA somatic mutation was identified in both FFPE and plasma samples, mutant cfDNA and tumor markers CA15-3 and CEA were quantified in a total of 27 serial plasma samples (Table 2).